US 7723317
RNAi modulation of ApoB and uses thereof
granted A61KA61K31/7105A61K31/718
Quick answer
US patent 7723317 (RNAi modulation of ApoB and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue May 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 20 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/7105, A61K31/718, A61P, A61P3/00